

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

ECMO, real world effectiveness of antivirals, molnupiravir trial, multilateralism lessons and innovations from COVID-19

Peer reviewed journals featured:

- A systematic review on prognostic factors associated with mortality in COVID-19 patients receiving venovenous ECMO [here](#) and associated commentary [here](#)
- A phase 2/3 trial of a bivalent Beta-containing booster COVID-19 vaccine [here](#)
- Randomised controlled trials of:
 - Daily use of lateral flow devices by contacts of COVID-19 cases in England [here](#) and associated commentary [here](#)
 - Colchicine and antithrombotic therapies in COVID-19 patients [here](#), [here](#) and [here](#)
- Observational studies on:
 - Real-world effectiveness of oral antivirals for community-dwelling COVID-19 outpatients in Hong Kong [here](#) and associated commentary [here](#)
 - The use of 'post-acute sequelae of COVID-19' diagnosis code in clinical practice [here](#)
 - Estimated global proportions of people with long COVID symptom clusters after symptomatic COVID-19 [here](#)
 - COVID-19 impact on long-term trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes [here](#) and associated commentary [here](#)
 - Rapid antigen tests' performance comparison between Delta and Omicron variants [here](#)
 - Severe COVID-19 and autoantibodies against angiotensin II [here](#)
 - Clinical phenotypes and outcomes associated with Omicron in critically ill patients [here](#)
 - Outcomes and a matched comparison group in the long-COVID in Scotland study [here](#)
 - COVID-19 vaccine effectiveness of primary series and booster doses in the US [here](#)
- Commentary on:
 - COVID-19 lessons and innovations on multilateralism in health [here](#)
 - Pandemic origins and a One Health approach to preparedness and prevention [here](#)
 - Mobilising evidence for improvement through learning networks in the pandemic [here](#)
 - It's time to redouble and refocus our efforts to fight COVID-19, not retreat [here](#)

Letters and correspondence discussed:

- Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron BA.2/BA.5 [here](#)
- A need to re-evaluate the WHO's Therapeutics and COVID-19 living guideline on mAbs [here](#)
- Immune imprinting and protection against repeat reinfection with SARS-CoV-2 [here](#)

Pre-peer review articles featured:

- Molnupiravir plus usual care vs usual care alone as early treatment for COVID-19 adults at increased risk of adverse outcomes in the UK [here](#)
- Long COVID risk and pre-COVID vaccination [here](#)
- Associations between reported post COVID-19 symptoms and subjective well-being in Israel [here](#)
- Immune response after SARS-CoV-2 infection with residual post COVID-19 symptoms [here](#)
- mRNA vaccination and COVID-19 illness and severity during Omicron BA.4/BA.5 periods [here](#)
- Effects of remdesivir in hospitalised patients with COVID-19 [here](#)

Guidance and reports

- The World Health Organization published its weekly epidemiological report on COVID-19 [here](#)
- The BMJ updated its best practice guide on COVID-19 [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)
- The National COVID-19 Clinical Evidence Taskforce released:
 - Updated recommendations and clinical flowcharts [here](#)
 - Guidance on care for adults with COVID-19 [here](#) and pregnancy and perinatal care [here](#)

News and blogs

- Lowest US life expectancy since 1996 linked to COVID-19 [here](#)
- The upcoming influenza season and protection from vaccines [here](#)
- COVID-19 jabs for kids [here](#)
- Had COVID? A delayed booster might lead to a better response [here](#)
- Antiviral purchased by UK government does not lower risk of hospital admission [here](#)
- Hospital admissions rise in England as some trusts reinstate mask requirements [here](#)
- The UK government is urged to expedite Evusheld treatment for vulnerable patients [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.